Valeritas (NSDQ:VLRX) said today that it inked an exclusive distribution deal with AMSL Diabetes and NZMS Diabetes for the commercialization of its V-Go wearable insulin delivery device in Australia and New Zealand.
According to the terms of the agreement, AMSL Diabetes and NZMS Diabetes retain the right to promote, market and sell the V-Go device to clinics and patients, while Valeritas remains responsible for regulatory and manufacturing activities. Financial terms of the deal were not disclosed.
On June 4-5, DeviceTalks Minnesota is taking over the Twin Cities medtech industry with one of the most anticipated conferences of the spring.
Join leaders from 3M, Abbott, Bigfoot Biomedical, Boston Scientific, Cardionomic, CMF Solutions, Cyient, Google Mayo Clinic, Medical Alley, Medtronic, NxThera, Opus College, Relievant Medsystems, University of Minnesota, Star Tribune, Smith & Nephew, Spry Health, Zimmer Biomet and many more when you register today.
Use the code "DTWeb" to save 15% on the cost of registration.